acetylated peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-26 and is reviewed periodically as new material appears.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
== Mechanism == It is a member of the secretin family of G protein-coupled receptors. The activity of this receptor is mediated by Gs protein, which activates adenylyl cyclase. Besides this, they also activate the phosphatidylinositol-calcium second messenger system.
Fully automatic polarimeters are now widely used and simply require the user to press a button and wait for a digital readout. Fast automatic digital polarimeters yield an accurate result within a few seconds, regardless of the rotation angle of the sample. In addition, they provide continuous measurement, facilitating high-performance liquid chromatography and other kinetic investigations. Another feature of modern polarimeters is the Faraday modulator. The Faraday modulator creates an alternating current magnetic field. It oscillates the plane of polarization to enhance the detection accuracy by allowing the point of maximal darkness to be passed through again and again and thus be determined with even more accuracy. As the temperature of the sample has a significant influence on the optical rotation of the sample, modern polarimeters have already included Peltier elements to actively control the temperature. Special techniques as temperature controlled sample tubes reduce measuring errors and ease operation. Results can directly be transferred to computers or networks for automatic processing. Historically, accurate filling of the sample cell had to be checked outside the instrument, as an appropriate control from within the device was not possible. Nowadays a camera system can help to monitor the sample and accurate filling conditions in the sample cell. Furthermore, features for automatic filling introduced by few companies are available on the market. When working with caustic chemicals, acids, and bases it can be beneficial to not load the polarimeter cell by hand.
== Signs and symptoms == Sun-sensitive rash with prominent poikiloderma and telangiectasias Juvenile cataracts Saddle nose Congenital bone defects, including short stature and radial ray anomalies such as absent thumbs Hair growth problems (absent eyelashes, eyebrows and/or hair) Hypogonadism has not been well documented Hypodontia Calcium problems (not documented in journals) Ear problems (not documented in journals but identified by patients in support groups) Produces osteosarcoma The skin is normal at birth. Between 3 and 6 months of age, the affected carrier develops poikiloderma on the cheeks. This characteristic "rash" that all RTS carriers have can develop on the arms, legs and buttocks. "Poikiloderma consists of areas of increased and decreased pigmentation, prominent blood vessels, and thinning of the skin."
Sources: en.wikipedia.org
==== Closed wounds ==== Hematomas (or blood tumor) – caused by damage to a blood vessel that in turn causes blood to collect under the skin. Hematomas that originate from internal blood vessel pathology are petechiae, purpura, and ecchymosis. The different classifications are based on size. Hematomas that originate from an external source of trauma are contusions, also commonly called bruises. Crush injury – caused by a great or extreme amount of force applied over a long period of time.
== Medical uses == Flunarizine is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an add-on in the treatment of epilepsy where its effect is weak and not recommended. It has been shown to significantly reduce ocular migraine frequency and severity in both adults and children.
Deepak L. Bhatt is an American interventional cardiologist, researcher, and educator. He is known for novel clinical trials in cardiovascular prevention, intervention, and heart failure. As of 2024, he is the director of Mount Sinai Fuster Heart Hospital in New York City and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai Health System. Prior, he served as the executive director of Interventional Cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and a professor of medicine at Harvard Medical School. He was given the American College of Cardiology's Distinguished Mentor Award in 2018, and in 2019, the American Heart Association (AHA) presented him with its Distinguished Scientist award, and as of 2025 he is president of the AHA New York City Board. As of 2025, Google Scholar reports that he has been cited 300,459 times, has an h-index of 207, and an i10-index of 1,261.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.